



Cara Therapeutics  
Investor Relations Department  
107 Elm St. 9th Flr  
Stamford, CT 06902  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: CARA

Last Trade:	13.14
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.37 <span style="color: red;">↓</span> (-2.739%)
Day Range	13.13 - 13.55
52-Week Range	5.27 - 28.50
Volume	756,277

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

We are developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. Our most advanced product candidate, intravenous, or I.V... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Aug 3, 2017*  
[Cara Therapeutics Reports Second Quarter 2017 Financial Results](#)
- Aug 3, 2017*  
[Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference](#)
- Aug 1, 2017*  
[Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer](#)
- Jul 27, 2017*  
[Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017](#)
- Jul 12, 2017*  
[Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease](#)

### Financials [\[ View all \]](#)

- Mar 10, 2017*  
[Annual Report \(10-K\)](#)
- May 10, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)